GT Biopharma Reports Second Quarter 2024 Financial Results, Provides Business Update

• GTB-3650 TriKE The Phase 1 study is expected to start in the second half of 2024, with first clinical data expected in the first half of 2025.
• GTB-5550 TriKE IND application for treatment of B7H3-positive solid tumors expected in 1H 2025
• The GTB-5550 Phase 1 dose-escalation basket trial is expected to start in 2025, evaluating six solid tumor types, including prostate, breast, head and neck, ovarian, lung, and gastrointestinal.
• GTB-7550 Tricycle is in preclinical development for autoimmune indications and targets CD19
• Cash of approximately $9.2 million from June 30, 2024, expected to be sufficient to finance activities until 2025

SAN FRANCISCO, CALIFORNIA, Aug. 14, 2024 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on the development of innovative therapies based on its proprietary natural killer (NK) cell engager, TriKE, platform, today announced financial results for the second quarter of 2024 for the period ended June 30, 2024.

“We are pleased to initiate a Phase 1 study evaluating GTB-3650 in cancer patients in the second half of this year. Initial data from the dose escalation phase of this study are expected in the first half of 2025. We also expect to file a second IND for GTB-5550 in the first half of 2025, which has much broader potential across multiple solid tumors and could fuel our future success as a company focused on NK cell engagers,” said Michael Breen, Executive Chairman and Interim Chief Executive Officer of GT Biopharma.